Serendex Pharmaceuticals A/S : secures credit facility

As per today, Serendex Pharmaceuticals A/S (OSE: SENDEX) has secured an undrawn committed credit facility in the amount of DKK 25 million provided by the major shareholder Sorana A/S. In combination with other economic components, this provides Serendex with a satisfactory cash situation for the remainder of 2016.

'This credit facility allows us to continue the development of GM-CSF for PAP and ARDS while further engaging in activities to secure a sustainable financial agreement with a strategic partner going forward', says Serendex CEO Kim Arvid Nielsen.

Serendex's annual report is due 4 April 2016.

For download 8 March Serendex secures credit facility

For further information, please contact:

Nadia Vega Vasiljev
Head of Communication and IR
Mobile [phone]
E-mail: [e-mail]

Kim Arvid Nielsen
CEO
Mobile [phone]
E-mail: [e-mail]

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess. Please visitwww.serendex.com to